GALE Galena Biopharma, Inc.

0.59
+0.0143  (2%)
Previous Close 0.57
Open 0.57
Price To book 0.78
Market Cap 21.97M
Shares 37,435,000
Volume 858,874
Short Ratio 12.28
Av. Daily Volume 714,127

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data presented March 2017.
GALE-301
Ovarian & Endometrial Cancer
Phase 3 trial terminated due to poor efficacy.
NeuVax (E75) - PRESENT
Low-to-intermediate HER2+ breast cancer
GALE-301 Phase 2a primary analysis presented at ASCO 2016.
GALE-301/302
Ovarian cancer
Phase 2 planned.
NeuVax
Gastric cancer
Phase 2b trial ongoing. Interim efficacy analysis due by the end of 2017.
NeuVax in combination with Herceptin
Breast cancer
Phase 3 trial to be initiated late 2017.
GALE-401
Essential Thrombocythemia (ET)
Phase 2 trial initiation announced December 14, 2016.
NeuVax
Ductal Carcinoma in Situ (DCIS)

Latest News

  1. AbbVie and J&J Present Positive Imbruvica Leukemia Data
  2. Galena Biopharma reports 1Q loss
  3. Galena Biopharma Reports First Quarter 2017 Financial Results
  4. Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
  5. Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss
  6. Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
  7. Zacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products
  8. Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
  9. DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
  10. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline - April 14, 2017
  11. FRIDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  12. GALE APRIL 14 ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE
  13. For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
  14. SEC Targets Fraud on Stock Tip-Sheet Websites
  15. 4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
  16. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Galena Biopharma, Inc. to Contact the Firm
  17. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  18. Deadline Alert: GPM Reminds Investors of the April 14 Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
  19. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline - April 14, 2017
  20. Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy